New Name, Renewed Purpose
Yasa Karsa Insani (YKI)’s new identity is guided by integrity, technical credibility, collaboration, innovation, humanity, and sustainability to strengthen Indonesia’s health systems and broaden its impact.
Vision & Mission
A healthy, resilient, and self-reliant Indonesia where every family thrives through equitable access to quality health systems, education, and innovation.
Our Values
Our Work
Yasa Karsa Insani (YKI) delivers technically sound, data-driven, and evidence-based solutions that strengthen Indonesia’s health systems and improve health access and quality for all.
Our core areas of expertise include:
Strategic Collaborations
Contributing to TB elimination and health issues in Indonesia
Intervention areas
Local community partners
Direct beneficiaries (people with TB, PLHIV, and communities)
Established in December 2016 as Yayasan KNCV Indonesia, YKI built on early collaboration with KNCV TB Foundation to strengthen Indonesia’s TB response. In 2017, YKI launched SITRUST, its first project, creating a national model for digital TB specimen transport and laboratory network strengthening.
Between 2018 and 2020, YKI advanced innovation through IMPAACT4TB, introducing the short-course 3HP TB preventive therapy and establishing national evidence for shorter regimens. The IO PPM strengthened collaboration between public and private sectors for TB care delivery. Meanwhile, AMPUH expanded YKI’s HIV portfolio, adapting SITRUST for nationwide specimen transport and laboratory support during the COVID-19 pandemic.
From 2021 to 2022, YKI led LIFT-TB, introducing and scaling up the 6-month BPaL/M regimen for drug-resistant TB, positioning Indonesia as the first country in Asia–Pacific to implement it programmatically. MANDIRI TB built a multisectoral resource mobilisation forum engaging government, private, academic, community, and media actors, while ENTAS TB strengthened district-level systems through SOBAT TB and TB DAP.
Between 2022 and 2023, YKI reinforced national HIV systems through AKSES VL, expanding viral load testing, data integration, and laboratory quality assurance. Concurrently, the 1to3 Study (continuation of IMPAACT4TB project) generated local evidence comparing 1HP and 3HP regimens, confirming safety and feasibility. Together, these initiatives showcased YKI’s technical leadership in clinical research and laboratory system strengthening.
From 2023 to 2024, YKI advanced health systems and community engagement. HARAPAN improved private-sector participation in Indonesia’s innovative TB financing model. In parallel, LOUDER TB, FTTC, and LOUDER2CureTB empowered TB survivors and advocates through digital and social media to raise awareness and drive demand for shorter, people-centred DR-TB treatment.
In 2025, YKI rebranded as Yasa Karsa Insani, reflecting its growth from a TB-focused organisation into a multidisciplinary health institution. The new identity signifies a broader commitment to communicable and non-communicable diseases, system resilience, and people-centred innovation, grounded in Yasa Karsa Insani (YKI) continued pursuit of technical excellence and impact.